

# STRATEGIC FRAMEWORK: 2023-2025



## Vision


A world in which people in need in low- and middle-income countries (LMICs) have rapid access to effective and affordable medical treatments and health technologies.



## Mission

Our mission is to increase equitable access to innovative medicines and other health technologies through public health-oriented voluntary licensing and technology transfer.

## OUR STRATEGIC GOALS



**01 EXPAND**  
Expand access to innovative medicines for **infectious diseases**

**02 ESTABLISH**  
Establish voluntary licensing as an **impactful access mechanism** for other diseases and conditions

**03 FACILITATE**  
Facilitate **development and access to novel medical technologies**

**04 ACCELERATE**  
Accelerate **equitable access to countermeasures for pandemics** and other international health emergencies

**05 SUPPORT**  
Support **diversified and sustainable manufacturing capacity**

## PRIORITY AREAS OF WORK

HIV, TB  
Viral Hepatitis  
Other infections

NCDs  
Maternal Health  
Paediatrics

Long-acting  
Biologics  
mRNA  
Vaccines

COVID-19  
Other health emergencies

Local & regional production  
Technology Transfer

### Core activities

- Developing an enabling environment
- In-licensing
- Out-licensing & licence management
- Patent mapping
- Supporting development & transfer of technology
- Supporting access

### Enablers

- Prioritisation
- Policy & advocacy
- Partnerships
- Patent info
- Regulatory info
- Upstream access commitments
- Communications
- Resource development
- Organisational effectiveness
- Review & learning

## TARGETS

**10** new licences concluded

**5** new products developed

by licensees and available for procurement, including 1 new formulation for children

**10** vaccine manufacturers

have received an initial mRNA technology transfer package

## IMPACT

**30** million people

per year benefit from access to MPP-licensed products saving **USD 1.2 billion**

